Ileana Andriola
Overview
Explore the profile of Ileana Andriola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosso G, dAndrea G, Barlati S, Di Nicola M, Andriola I, Marcatili M, et al.
Curr Neuropharmacol
. 2025 Jan;
23(5):e1570159X337670.
PMID: 39810448
Introduction/objective: Data on long-term treatment with Esketamine Nasal Spray (ESKNS) in real-world patients with treatment resistant depression (TRD) is scarce. The primary aim of the study is to evaluate the...
2.
Andriola I, Valt C, Marsella V, Palma C, Tavella A, Putignano F, et al.
J Psychiatr Res
. 2024 Nov;
181():126-133.
PMID: 39612606
Mismatch negativity (MMN) is widely considered a candidate diagnostic biomarker for schizophrenia (SCZ). Although blunted MMN responses have been reliably observed in psychosis, the evidence for MMN deficits in other...
3.
dAndrea G, Miuli A, Pettorruso M, Cavallotto C, Marrangone C, Cocco A, et al.
J Affect Disord
. 2024 Sep;
367:583-588.
PMID: 39233241
Background: Treatment-Resistant Depression (TRD) affects almost 30 % of patients with Major Depressive Disorder (MDD). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin...
4.
dAndrea G, Pettorruso M, Di Lorenzo G, Rhee T, Chiappini S, Carullo R, et al.
J Affect Disord
. 2023 Dec;
348:314-322.
PMID: 38145840
Introduction: Intravenous ketamine (KET-IV) and intranasal esketamine (ESK-NS) are effective in the acute treatment of Treatment-Resistant Depression (TRD). Studies comparing KET-IV and ESK-NS concerning their action, safety, and tolerability are...
5.
Pettorruso M, Guidotti R, dAndrea G, De Risio L, DAndrea A, Chiappini S, et al.
Psychiatry Res
. 2023 Aug;
327:115378.
PMID: 37574600
Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data...
6.
dAndrea G, Chiappini S, McIntyre R, Stefanelli G, Carullo R, Andriola I, et al.
Am J Geriatr Psychiatry
. 2023 Jul;
31(12):1032-1041.
PMID: 37479669
Introduction: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with...
7.
Chiappini S, dAndrea G, De Filippis S, Di Nicola M, Andriola I, Bassetti R, et al.
Eur Neuropsychopharmacol
. 2023 May;
74:15-21.
PMID: 37148637
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated...
8.
Martinotti G, DellOsso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M, et al.
Bipolar Disord
. 2023 Jan;
25(3):233-244.
PMID: 36636839
Background: Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not...
9.
Rocca P, Rucci P, Montemagni C, Rossi A, Bertolino A, Aguglia E, et al.
Eur Psychiatry
. 2023 Jan;
66(1):e10.
PMID: 36628577
Background: Deficits in social cognition (SC) are significantly related to community functioning in schizophrenia (SZ). Few studies investigated longitudinal changes in SC and its impact on recovery. In the present...
10.
Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, DellOsso B, et al.
J Affect Disord
. 2022 Sep;
319:646-654.
PMID: 36167246
Background: Treatment-resistant Depression (TRD) represents a widespread disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer of ketamine, has been recently approved for TRD, but real-world studies are...